MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

54.68 -1.50 (-2.67%)
Streaming Delayed Price Updated: 12:41 PM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
36 37 Next >
News headline image
Cathie Wood's Ark Invest Sells Nearly $11.5M Worth Of Coinbase Shares As Bitcoin, Crypto Rally Loses Steam ↗
 
Via Benzinga
News headline image
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine ↗
Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. 
Via Investor's Business Daily
News headline image
Could Intellia Therapeutics Become the Next CRISPR Therapeutics? ↗
Intellia is approaching the finish line. 
Via The Motley Fool
News headline image
Cathie Wood's Ark Dumps $12.8M Worth Of Grayscale Bitcoin Trust Amid Crypto Rally Losing Wind In Sails ↗
On Monday, Cathie Wood-led Ark Invest made a significant move by selling over $12.8 million worth of Grayscale Bitcoin Trust (OTC:GBTC) shares, amidst fluctuating cryptocurrency prices. 
Via Benzinga
News headline image
Why CRISPR Stock Keeps Falling ↗
CRISPR just scored its first FDA victory -- but profits remain years away. 
Via The Motley Fool
News headline image
Is This News a Setback or a Step Forward for CRISPR Therapeutics? ↗
It's important to look at the news through a long-term lens. 
Via The Motley Fool
News headline image
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for CRISPR Therapeutics ↗
 
Via Benzinga
News headline image
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023 ↗
Some of the most explosive opportunities can be found in biotech stocks. In fact, as we head into New Year 2024, here are three to consider. 
Via InvestorPlace
News headline image
HP To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Bull Of The Day: Crispr Therapeutics ↗
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old... 
Via Talk Markets
News headline image
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug? ↗
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider. 
Via The Motley Fool
News headline image
The 3 Best Cathie Wood Stocks to Buy in December ↗
Cathie Wood stocks had a great November and are well-positioned to keep performing well, given the favorable macro backdrop. 
Via InvestorPlace
News headline image
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy? ↗
The big biotech's shares have been on the rise this year. 
Via The Motley Fool
News headline image
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder ↗
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y 
Via Benzinga
News headline image
Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review ↗
Treasury yields and crude oil came off multimonth lows on Friday's jobs report. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried? ↗
The timing of the cuts is setting off alarm bells, but the situation is under control. 
Via The Motley Fool
News headline image
Healthcare Gems: 3 Essential Long-Term Stock Picks ↗
Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks. 
Via InvestorPlace
News headline image
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics ↗
Shareholders will do well to prepare themselves for how regulators might react. 
Via The Motley Fool
News headline image
5 Unstoppable Trends to Invest $1,000 in for 2024 ↗
These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year. 
Via The Motley Fool
News headline image
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy ↗
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. 
Via InvestorPlace
News headline image
CRISPR Therapeutics' Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases ↗
Monday, CRISPR Therapeutics AG (NASDAQ: CRSP) provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T  
Via Benzinga
News headline image
Better Growth Stock: CRISPR Therapeutics vs. Invitae ↗
One of these stocks may be riskier than the other... 
Via The Motley Fool
News headline image
The Market's Up This Year. Do You Feel Like You Are Winning? ↗
We've also got a look at two stocks worth watching and the popular toys for this holiday season. 
Via The Motley Fool
News headline image
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
News headline image
Where Will Vertex Pharmaceuticals Be in 10 Years? ↗
Vertex shares have soared 400% over the past decade. 
Via The Motley Fool
News headline image
If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today ↗
CRISPR Therapeutics' shares advanced in the double-digits this year. 
Via The Motley Fool
News headline image
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now ↗
The one thing these two stocks have in common is tremendous growth prospects. 
Via The Motley Fool
News headline image
An Important History Lesson for Gene-Editing Investors ↗
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy. 
Via The Motley Fool
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story